Best Osteosarcoma Treatment Centers in the United States
Untitled Document
Everything you learn from this Web site should
be discussed with your physician. Even though I have strong opinions
about various treatment options, you should consult with a physician before
embarking on a treatment plan.
The following patient-oriented web site is presented by Dr. James Wittig of The Mount Sinai Medical Center in New York City.
It will be helpful for all newly diagnosed osteosarcoma patients and their
families (External Websites):
In California, a good place to start is with Dr. Sant P. Chawla at the Sarcoma Oncology Center in Santa Monica, California.
The latest Osteosarcoma study that I am aware
of, Best record for ten-year Osteosarcoma
treatment showed a 92% 5-year overall survival rate and an 84% event-free
10-year survival rate but the therapy was, at best a difficult, three month,
cell-toxic chemotherapy and at worst, a nine month long cell-toxic chemotherapy.
Depending on the stage of bone tumor growth, a total knee replacement
can be necessary as well or an amputation if that is not possible. Note: knee replacements are subject to infections at which time amputation is usually the only method of stopping the infection.
List of top Osteosarcoma
treatment centers
 |
Presbyterian/St Luke’s Medical Center Top |
|
|
The University of Texas M. D. Anderson Cancer Center 1515 Holcombe Blvd, Houston, TX 77030 1-800-392-1611 (USA) / 1-713-792-6161 M.D. Anderson Cancer Center Web site
Top |
|
|
|
 |
Top
Superior survival in treatment of primary nonmetastatic pediatric
osteosarcoma of the extremity.
Wilkins RM, Cullen JW, Odom L, Jamroz BA, Cullen PM, Fink K, Peck SD, Stevens
SL, Kelly CM, Camozzi AB.
Institute for Limb Preservation at Presbyterian/St. Luke’s Medical Center,
Denver, Colorado 80210, USA.
BACKGROUND: A protocol to treat osteosarcoma of the extremity was developed at
two local institutions.
METHODS: The study involved a dose-intensified neoadjuvant
(pre-operative) protocol of intravenous doxorubicin and intra-arterial cisplatin
administered repetitively until maximum angiographic response was noted.
Definitive surgery was delayed until > or =90% reduction in tumor neovascularity
was documented.
Prospective assessment of serial arteriograms was highly
accurate (94%) in predicting histological response and assisted in surgical
planning.
After resection, if patients were determined to be good responders (>
or =90% tumor necrosis), they underwent a 4-month postoperative course with the
same agents.
Poor responders (<90% necrosis) were treated with alternative
agents for 12 months from diagnosis.
Forty-seven assessable patients with
primary, high-grade, nonmetastatic osteosarcoma of the extremity were included
in this analysis.
The median age was 15 years (range, 7-21 years).
RESULTS:
Patients underwent an average of four preoperative intra-arterial courses.
Forty-three patients underwent limb-preservation procedures, and 41 had >90%
tumor necrosis.
With an average follow-up of 92 months (range, 20-178 months),
39 patients were continuously disease free, 3 died of disease, 1 died of other
causes, and 4 have no evidence of disease 11 to 51 months after relapse (all
pulmonary metastases).
There were no local recurrences.
Kaplan-Meier analysis
demonstrated a 10-year overall survival of 92% and an event-free survival of
84%.
CONCLUSIONS: This study demonstrates excellent survival with a
dose-intensified neoadjuvant protocol. Future endeavors should involve a
multi-institutional randomized study comparing this approach with another
multiagent intravenous neoadjuvant protocol.
Publication Types:
* Clinical Trial
* Multicenter Study
PMID: 12794015 [PubMed - indexed for MEDLINE]
